AZN - This Analyst Slightly Lowers AstraZeneca Forecast Amid Earnings Concerns Although Still Bullish on Future Growth Potential | Benzinga
Thursday, AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter 2023 sales of $12.02 billion, up 7% Y/Y (+8% at constant currency), slightly below the consensus of $12.09 billion, fueled by strong global demand growth for cancer drugs.
Excluding COVID-19 medicines, fourth quarter 2023 revenue increased by 16% to $12.04 billion.
The company reported a core EPS of $1.45, up 5% (+7% on constant currency), with earnings per ADS reached $0.72, missing the consensus of $0.79.
Also Read: AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies.
BMO Capital Markets is updating its model following the earnings and notes that ...